Abstract |
A cooperative phase II study of cisplatin in head and neck cancer was conducted in 23 institutions. Eighty-nine patients were entered into this trial, of which 73 were evaluable. Two different regimens were employed in this study. Regimen A: cisplatin 10 mg/m2 intravenous (i.v.) infusion daily, days 1-5, q 3 wk. Regimen B: cisplatin 50 mg/m2 i.v. infusion, day 1, q 3 wk. Two patients achieved complete response and 17 achieved partial response with an overall response rate of 26.0%. By histological types, the response rate was 26.3% in the case of squamous cell carcinoma. Partial response were observed in 2 cases of adenocarcinoma and in one case each of adenoid cystic carcinoma and transitional cell carcinoma. The response rate was 19.4% for previously treated patients, as compared to 63.6% for the previously untreated group. Toxic effects were observed in 94.7% of 76 evaluable cases. From 50 to 68% of patients experienced nausea, vomiting and anorexia. No patient exhibited a serum creatinine level exceeding 2 mg/dl. Anemia and leukopenia were observed in 58.9% and 32.9% respectively. It is therefore concluded that cisplatin is markedly useful for the treatment of head and neck cancer.
|
Authors | Y Inuyama, C Takeda |
Journal | Gan to kagaku ryoho. Cancer & chemotherapy
(Gan To Kagaku Ryoho)
Vol. 13
Issue 2
Pg. 232-8
(Feb 1986)
ISSN: 0385-0684 [Print] Japan |
PMID | 3004363
(Publication Type: English Abstract, Journal Article)
|
Chemical References |
|
Topics |
- Adenocarcinoma
(drug therapy)
- Adult
- Aged
- Carcinoma, Adenoid Cystic
(drug therapy)
- Carcinoma, Squamous Cell
(drug therapy)
- Cisplatin
(administration & dosage, therapeutic use)
- Drug Administration Schedule
- Drug Evaluation
- Female
- Head and Neck Neoplasms
(drug therapy)
- Humans
- Infusions, Parenteral
- Male
- Middle Aged
- Mouth Neoplasms
(drug therapy)
- Nose Neoplasms
(drug therapy)
- Paranasal Sinus Neoplasms
(drug therapy)
|